Savvy Stock Picks

OCZ Technology Group Inc. (NASDAQ:OCZ) increased 4.05%, to close at $5.40 and its overall traded volume was 578,987.00 shares during the last session against its average volume of 445,308.00. OCZ opened the day at $5.16, it made an intraday low of $5.01 and an intraday high of $5.43. The stock has a 52 week low of $1.79 and 52 week high of $6.25. OCZ’s market capitalization is 144.04M and it has 26.67M outstanding shares. OCZ Technology Group, Inc. (OCZ) is a provider of high performance solid state drives (SSDs) and memory modules for computing devices and systems. In addition to its SSD and Memory Module product lines, the Company also designs, develops, manufactures and distributes other high performance components for computing devices and systems, including thermal management solutions and alternating current/direct current (AC/DC) switching power supply units (PSUs). The Company offers its customers flexibility and customization by providing a range of solutions, which are interoperable and can be configured alone or in combination to make computers run faster. Through its diversified and global distribution channel, it offers more than 450 products to 376 customers, including retailers, online retailers (etailers), original equipment manufacturers (OEMs) and computer distributors. In February 2010, OCZ divested its Hypersonic Personal Computer (PC) Systems product lines.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) decreased -0.06%, to close at $7.84 and its overall traded volume was 578,776.00 shares during the last session against its average volume of 634,321.00. CHTP opened the day at $7.85, it made an intraday low of $7.41 and an intraday high of $7.98. The stock has a 52 week low of $1.94 and 52 week high of $8.10. CHTP’s market capitalization is 385.39M and it has 49.13M outstanding shares. Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) increased 6.29%, to close at $1.86 and its overall traded volume was 576,892.00 shares during the last session against its average volume of 195,213.00. PSTI opened the day at $1.75, it made an intraday low of $1.74 and an intraday high of $1.87. The stock has a 52 week low of $0.94 and 52 week high of $1.87. PSTI’s market capitalization is 48.96M and it has 26.32M outstanding shares. Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company’s PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.

United Western Bancorp, Inc. (NASDAQ:UWBK) decreased -6.84%, to close at $0.388 and its overall traded volume was 576,811.00 shares during the last session against its average volume of 349,141.00. UWBK opened the day at $0.40, it made an intraday low of $0.36 and an intraday high of $0.41. The stock has a 52 week low of $0.28 and 52 week high of $3.43. UWBK’s market capitalization is 11.42M and it has 29.43M outstanding shares. United Western Bancorp, Inc. (United Western Bancorp) is a unitary thrift holding company. The Company’s operations are conducted primarily through United Western Bank (United Western Bank or the Bank), UW Trust Company (UW Trust), Matrix Financial Services Corporation (Matrix Financial), UWBK Fund Management, Inc., (Fund Management) and UW Investment Services Inc. (UWIS), all of which are wholly owned subsidiaries of the Company. As of December 31, 2009, it had eight full service banking locations in the Colorado Front Range marketplace (downtown Denver, Cherry Creek, Hampden, Centennial, Boulder, Loveland, Fort Collins and Longmont), and a loan production office servicing the Aspen and Roaring Fork Valley market areas.

Impax Laboratories, Inc. (NASDAQ:IPXL) increased 0.00%, to close at $20.68 and its overall traded volume was 576,578.00 shares during the last session against its average volume of 596,970.00. IPXL opened the day at $21.00, it made an intraday low of $20.49 and an intraday high of $21.00. The stock has a 52 week low of $0.18 and 52 week high of $22.39. IPXL’s market capitalization is 1.33B and it has 64.24M outstanding shares. Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals. In the generic pharmaceuticals market, the Company focuses on controlled-release generic versions of brand-name pharmaceuticals, covering a range of therapeutic areas. In the brand-name pharmaceuticals market, the Company is developing products for the treatment of central nervous system (CNS) disorders. The Company’s brand-name product portfolio consists of development-stage projects to which the Company applies its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. It operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division).